Journal: OncoTargets and Therapy

Article Title: Evaluation of p53 gene expression and prognosis characteristics in uveal melanoma cases

doi: 10.2147/ott.s136785

Figure Lengend Snippet: Figure 1 Expressions of p53 mRNA in (A) MUM-2B, C918, and (B) D78 cells as detected by RT-PCR. Abbreviations: mRNA, messenger RNA; RT-PCR, real-time polymerase chain reaction.

Article Snippet: Primary antibodies used for immunohistochemical evaluation included an antihuman polyclonal p53 antibody (1:500, clone CM1; Beijing Zhongshan Golden Bridge Biotechnology Co., Ltd.).

Techniques: Reverse Transcription Polymerase Chain Reaction, Real-time Polymerase Chain Reaction

Journal: OncoTargets and Therapy

Article Title: Evaluation of p53 gene expression and prognosis characteristics in uveal melanoma cases

doi: 10.2147/ott.s136785

Figure Lengend Snippet: Figure 2 Expression of p53 protein in MUM-2B, C918, and D78 cells as detected by Western blot.

Article Snippet: Primary antibodies used for immunohistochemical evaluation included an antihuman polyclonal p53 antibody (1:500, clone CM1; Beijing Zhongshan Golden Bridge Biotechnology Co., Ltd.).

Techniques: Expressing, Western Blot

Journal: OncoTargets and Therapy

Article Title: Evaluation of p53 gene expression and prognosis characteristics in uveal melanoma cases

doi: 10.2147/ott.s136785

Figure Lengend Snippet: Figure 4 The cell invasion ability was measured by a transwell assay at 48 hours after p53 overexpression in cells. Note: Magnification ×200.

Article Snippet: Primary antibodies used for immunohistochemical evaluation included an antihuman polyclonal p53 antibody (1:500, clone CM1; Beijing Zhongshan Golden Bridge Biotechnology Co., Ltd.).

Techniques: Transwell Assay, Over Expression

Journal: OncoTargets and Therapy

Article Title: Evaluation of p53 gene expression and prognosis characteristics in uveal melanoma cases

doi: 10.2147/ott.s136785

Figure Lengend Snippet: Figure 3 Expression of p53 protein in pathological tissues as detected by immunohistochemistry method (400×).

Article Snippet: Primary antibodies used for immunohistochemical evaluation included an antihuman polyclonal p53 antibody (1:500, clone CM1; Beijing Zhongshan Golden Bridge Biotechnology Co., Ltd.).

Techniques: Expressing, Immunohistochemistry

Journal: Frontiers in Nutrition

Article Title: Sulforaphane attenuates aldose reductase-mediated platelet dysfunction in high glucose-stimulated human platelets via downregulation of the Src/ROS/p53 signaling pathway

doi: 10.3389/fnut.2025.1663245

Figure Lengend Snippet: Sulforaphane downregulates AR-mediated ROS/p53 signaling in HG-stimulated human platelets. (A–D) Washed human platelets were pre-incubated with SFN (5, 10, or 20 μM) or vehicle control for 40 min, followed by stimulation with NG or HG for additional 90 min. (A,B) Intraplatelet ROS levels were measured by flow cytometry. (C,D) Platelets were lysed and phosphorylation of p38α MAPK (C) and p53 (D) were determined by Western blotting. (E–J) Washed human platelets were pre-incubated with SFN (20 μM) with or without a ROS scavenger NAC (500 μM) (E–G) or ARI (10 μM) (H–J) for 40 min, followed by stimulation with NG or HG for additional 90 min. Intraplatelet ROS levels (E,H) , and phosphorylation of p38α MAPK (F,I) and p53 (G,J) were determined. Data were assessed by a one-way ANOVA followed by Dunnett’s t -test in (A–D) and by Tukey’s multiple comparisons test in (E–J) ( n = 3). * p < 0.05, ** p < 0.01 and *** p < 0.001 vs. the vehicle control; # p < 0.05 and ## p < 0.01; ns, not significant difference.

Article Snippet: Antibody against phospho-p53 was purchased from OriGene (MD, USA).

Techniques: Incubation, Control, Flow Cytometry, Phospho-proteomics, Western Blot

Journal: Frontiers in Nutrition

Article Title: Sulforaphane attenuates aldose reductase-mediated platelet dysfunction in high glucose-stimulated human platelets via downregulation of the Src/ROS/p53 signaling pathway

doi: 10.3389/fnut.2025.1663245

Figure Lengend Snippet: Sulforaphane attenuates ROS/p53 signaling through downregulating AR-mediated activation of Src family kinases in HG-stimulated human platelets. (A) Washed human platelets were pre-incubated with SFN (5, 10, or 20 μM) or vehicle control for 40 min, followed by stimulation with NG or HG for additional 90 min. Platelets were lysed and Src phosphorylation was determined by Western blotting. (B) Washed human platelets were pre-incubated with SFN (20 μM) with or without ARI (10 μM) for 40 min, followed by stimulation with NG or HG for additional 90 min. Src phosphorylation was determined. (C–G) Washed human platelets were pre-incubated with SFN (20 μM) with or without a Src inhibitor PP2 (20 μM) for 40 min, followed by stimulation with NG or HG for additional 90 min. Src phosphorylation (C) , intraplatelet ROS levels (D,E) , and phosphorylation of p38α MAPK (F) and p53 (G) were determined. Data were assessed by a one-way ANOVA followed by Dunnett’s t -test in (A) and by Tukey’s multiple comparisons test in (B–G) ( n = 3). * p < 0.05, ** p < 0.01 and *** p < 0.001 vs. the vehicle control; ns, not significant difference.

Article Snippet: Antibody against phospho-p53 was purchased from OriGene (MD, USA).

Techniques: Activation Assay, Incubation, Control, Phospho-proteomics, Western Blot

Journal: Frontiers in Nutrition

Article Title: Sulforaphane attenuates aldose reductase-mediated platelet dysfunction in high glucose-stimulated human platelets via downregulation of the Src/ROS/p53 signaling pathway

doi: 10.3389/fnut.2025.1663245

Figure Lengend Snippet: Sulforaphane attenuates AR-mediated platelet dysfunction mainly through downregulating Src/ROS/p53 signaling in HG-stimulated human platelets. Washed human platelets were pre-incubated with SFN (20 μM) with or without PP2 (20 μM) (A–D) , NAC (500 μM) (E–H) , or a p53 inhibitor PFT-μ (20 μM) (I–L) for 40 min, followed by stimulation with NG or HG for additional 90 min. Platelet Δψm dissipation (A,E,I) and PS exposure (B,F,J) were determined using flow cytometry. Platelet aggregation was stimulated by 1 μg/mL collagen (C,G,K) . Platelet surface expression of CD62P was analyzed by flow cytometry (D,H,L) . Data were assessed by a one-way ANOVA followed by Tukey’s multiple comparisons test ( n = 3). * p < 0.05, ** p < 0.01 and *** p < 0.001 vs. the vehicle control; # p < 0.05, ## p < 0.01, and ### p < 0.001; ns, not significant difference.

Article Snippet: Antibody against phospho-p53 was purchased from OriGene (MD, USA).

Techniques: Incubation, Flow Cytometry, Expressing, Control

Journal: Frontiers in Nutrition

Article Title: Sulforaphane attenuates aldose reductase-mediated platelet dysfunction in high glucose-stimulated human platelets via downregulation of the Src/ROS/p53 signaling pathway

doi: 10.3389/fnut.2025.1663245

Figure Lengend Snippet: Proposed mechanism of SFN in attenuating platelet dysfunction under HG conditions. SFN alleviates HG-induced platelet mitochondrial dysfunction, apoptosis, and hyperreactivity primarily through suppression of AR activity. This inhibition downregulates the Src/ROS/p53 signaling pathway, ultimately protecting against hyperglycemia-associated atherothrombosis by normalizing platelet function.

Article Snippet: Antibody against phospho-p53 was purchased from OriGene (MD, USA).

Techniques: Activity Assay, Inhibition

Journal: Cancer Immunology, Immunotherapy : CII

Article Title: Study on pathological factors affecting the sensitivity of neoadjuvant therapy in hypopharyngeal cancer

doi: 10.1007/s00262-025-03957-w

Figure Lengend Snippet: A. Differences in P53 expression between different therapeutic groups, ** p = 0.0017; B. Differences in P16 expression between different therapeutic groups, p = 0.0880; C. Differences in Ki67 expression between different therapeutic groups, ** p = 0.0005; D. Relationship between the combination of P53 and Ki67 expression levels and the efficacy. ** p < 0.01

Article Snippet: The incubation temperature and time of P16 protein antibody, Ki-67 protein antibody and P53 protein antibody were 37 °C for 40 min. Reagents were purchased from Beijing Zhongshan Jinqiao Company.

Techniques: Expressing

Journal: Cancer Immunology, Immunotherapy : CII

Article Title: Study on pathological factors affecting the sensitivity of neoadjuvant therapy in hypopharyngeal cancer

doi: 10.1007/s00262-025-03957-w

Figure Lengend Snippet: Relationship between the combination of P53 and Ki67 expression levels and the efficacy

Article Snippet: The incubation temperature and time of P16 protein antibody, Ki-67 protein antibody and P53 protein antibody were 37 °C for 40 min. Reagents were purchased from Beijing Zhongshan Jinqiao Company.

Techniques: Expressing

Journal: Cancer Immunology, Immunotherapy : CII

Article Title: Study on pathological factors affecting the sensitivity of neoadjuvant therapy in hypopharyngeal cancer

doi: 10.1007/s00262-025-03957-w

Figure Lengend Snippet: The immunohistochemical expression of Ki67 and P53 in different efficacy groups (100X). A.Ki67 < 60; B.Ki67 ≥ 60; C. P53 mutant; D.P53 wild type

Article Snippet: The incubation temperature and time of P16 protein antibody, Ki-67 protein antibody and P53 protein antibody were 37 °C for 40 min. Reagents were purchased from Beijing Zhongshan Jinqiao Company.

Techniques: Immunohistochemical staining, Expressing, Mutagenesis

Journal: Cancer Immunology, Immunotherapy : CII

Article Title: Study on pathological factors affecting the sensitivity of neoadjuvant therapy in hypopharyngeal cancer

doi: 10.1007/s00262-025-03957-w

Figure Lengend Snippet: Correlation analysis between pathological indicators and efficacy in different neoadjuvant therapies. A. Differences in therapeutic efficacy among patients with different expressions of P53, P16, and Ki67 in the neoadjuvant chemotherapy group; B. Differences in therapeutic efficacy among patients with different P53, P16, and Ki67 expression in the neoadjuvant targeted + chemotherapy group; C. Differences in therapeutic efficacy among patients with different expressions of P53, P16, and Ki67 in the neoadjuvant immunotherapy + chemotherapy group. * p < 0.05

Article Snippet: The incubation temperature and time of P16 protein antibody, Ki-67 protein antibody and P53 protein antibody were 37 °C for 40 min. Reagents were purchased from Beijing Zhongshan Jinqiao Company.

Techniques: Drug discovery, Expressing

Journal: Molecular Medicine Reports

Article Title: Pan-cancer analysis of the carcinogenic role of WSB2 in human tumors

doi: 10.3892/mmr.2025.13625

Figure Lengend Snippet: WSB2 promotes the proliferation and migration of breast cancer cells. (A) Reverse transcription-quantitative PCR and (B) western blotting were used to detect the effect of WSB2 overexpression in MDA-MB-231 and MCF-7 cells. (C) Viability of MDA-MB-231 and MCF-7 cells was evaluated using a CCK-8 assay. (D) Representative images and (E) the quantification of the number of MDA-MB-231 and MCF-7 cells in the S phase evaluated using an 5 ethynyl-2′-deoxyuridine assay. (F) Representative images of colony formation ability of MDA-MB-231 and MCF-7cells. (G) Representative images and (H) quantification of wound healing and (I) colony formation ability of MDA-MB-231 and MCF-7cells. (J) Transwell assays to determine the migration ability of MDA-MB-231and MCF-7cells. (K) ERK1/2, p53 and PCNA and (L) Snail, E-cadherin and Vimentin protein levels in MDA-MB-231 and MCF-7 cells were detected using western blotting. *P<0.05, **P<0.01, ***P<0.001. WSB2, WD repeat and SOCS box containing 2.

Article Snippet: Standard technique was used to carry out western blotting ( ) and the following specific primary antibodies were used: Anti-WSB2 (cat. no. ab127176; Abcam, 1:2,000), anti-GADPH (cat. no. CSB-MA000071Mom; Cusabio Technology, LLC, 1:10,000), anti-β-Actin (cat. no. AC026; ABclonal Biotech Co., Ltd. 1:10,000 dilution), anti-HA-tag (cat. no. B1021; Suzhou Botelon Immunotechnology Co., Ltd. 1:5,000), anti-E-cadherin (cat. no. BD-PT1454; Suzhou Botelon Immunotechnology Co., Ltd.; 1:500 dilution), anti-proliferating cell nuclear antigen (PCNA; cat. no. D220014-0025; Sangon Biotech Co., Ltd. 1:1,000 dilution), anti-Vimentin (cat. no. BD-PB4686; Suzhou Botelon Immunotechnology Co., Ltd. 1:500), anti-p53 antibody (p53) (cat. no. CSB-PA07889A0Rb; Cusabio Technology, LLC.

Techniques: Migration, Reverse Transcription, Real-time Polymerase Chain Reaction, Western Blot, Over Expression, CCK-8 Assay

Journal: Oncology Letters

Article Title: Fenofibrate attenuates the cytotoxic effect of cisplatin on lung cancer cells by enhancing the antioxidant defense system in vitro

doi: 10.3892/ol.2023.13899

Figure Lengend Snippet: Effects of FF and WY on CDDP-induced DNA damage response. A549 cells were pretreated with 50 µM FF, 50 µM WY, or vehicle alone for 24 h, followed by exposure to 40 µM CDDP for 24 or 48 h (i.e., 24 h unless indicated) in the presence or absence of FF or WY. (A and B) Immunofluorescence of γH2AX expression. (A) Representative images of γH2AX expression (green); cell nuclei were counterstained with DAPI (blue); the arrowheads indicate γH2AX-positive cells. (B) The percentages of γH2AX-positive cells are shown. Data are expressed as the mean and standard error of the mean (n=4). **P < 0.01 using the two-way ANOVA and Tukey-Kramer test t; ns, not significant; Co, control. (C and D) Western blot analyses for the expression of p53, p-p53, and HSP70 (C); and Bcl-2, Bcl-xL, Bax, and Bad (D) are shown. The relative protein levels were estimated using densitometry and normalized to the level of β-actin as a loading control. Data are expressed as the mean and standard error of the mean (n=4). **P < 0.01 using the one-way ANOVA and Tukey-Kramer test. FF, fenofibrate; WY, WY14643; CDDP, cisplatin; γH2AX, γH2A histone family member X; DAPI, 4′,6-diamidino-2-phenylindole; p-p53, phosphorylated p53; HSP70, heat shock protein 70; Bcl-2, B-cell/CLL lymphoma 2; Bcl-xL, B-cell lymphoma-extra large; Bax, Bcl-2-associated X protein; Bad, Bcl-2 antagonist of cell death.

Article Snippet: The primary antibodies used in this study were mouse monoclonal anti-β-actin (017-24573, Wako, Tokyo, Japan); rabbit polyclonal anti-Lamin B1 (12987-1-AP, Proteintech Group, Inc., Tokyo, Japan); rabbit polyclonal anti-α-tubulin (PM054-7, Medical & Biological Laboratories Co., Ltd., Tokyo, Japan); mouse monoclonal anti-p53 (sc-126, Santa Cruz Biotechnology), rabbit polyclonal anti-phosphorylated p53 (CSB-PA157242, Cusabio Biotech Co., Ltd., Houston, TX, USA); mouse monoclonal anti-heat shock protein 70 (HSP70) (SPA-810, Stressgen Biotechnologies Co., Ltd., Seoul, Korea); rabbit polyclonal anti-B-cell/CLL lymphoma 2 (Bcl-2) (12789-1-AP, Proteintech Group); rabbit polyclonal anti-B-cell lymphoma-extra large (Bcl-xL) (10783-1-AP, Proteintech Group); rabbit polyclonal anti-Bcl-2-associated X protein (Bax) (50599-2-Ig, Proteintech Group); mouse monoclonal anti-Bcl-2 antagonist of cell death (Bad) (B36420, BD Transduction Laboratories, Lexington, KY, USA); rabbit polyclonal anti-superoxide dismutase (SOD) 1 (GTX100554, GeneTex, Inc., Irvine, CA, USA); rabbit polyclonal anti-SOD2 (GTX116093, GeneTex); rabbit polyclonal anti-heme oxygenase (HO)-1 (GTX101147, GeneTex); rabbit polyclonal anti-catalase (GTX110704, GeneTex); rabbit monoclonal anti-nuclear factor erythroid 2-related factor 2 (Nrf2) (ab62352, Abcam, Cambridge, UK); mouse monoclonal anti-Kelch-like ECH-associated protein 1 (Keap1) (M224-3, Medical & Biological Laboratories Co., Ltd.); rabbit polyclonal anti-β-transduction repeat containing protein (β-TrCP) (GTX102667, GeneTex); rabbit polyclonal anti-aryl hydrocarbon receptor (AhR) (28727-1-AP, Proteintech Group); and mouse monoclonal anti-ubiquitin (sc-8017, Santa Cruz Biotechnology, Dallas, TX, USA).

Techniques: Immunofluorescence, Expressing, Control, Western Blot